Nifty
:
22147.90
Sensex
:
72943.68
-124.60 (-0.56%)
-456.10 (-0.62%)
Nifty
Sensex
:
:
22147.90
72943.68
-124.60 (-0.56%)
-456.10 (-0.62%)

Windlas Biotech Ltd.

Pharmaceuticals & Drugs

Rating :
69/99

BSE: 543329 | NSE: WINDLAS

NSE BSE
529.50
16-Apr-2024
  • Open
  • High
  • Low
  • Previous Close
  •  526.65
  •  531.95
  •  520.30
  •  528.45
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  37125
  •  195.40
  •  590.85
  •  246.05

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 1,102.32
  • 20.94
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 1,077.13
  • 0.75%
  • 2.56

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 62.82%
  • 1.08%
  • 21.19%
  • FII
  • DII
  • Others
  • 1.18%
  • 10.37%
  • 3.36%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.62
  • 10.80
  • 6.26

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.31
  • 9.35
  • 1.95

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 12.78
  • -7.97
  • 38.63

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 16.58

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 1.73

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 9.21

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 23
Dec 22
Var%
Sep 23
Sep 22
Var%
Jun 23
Jun 22
Var%
Mar 23
Mar 22
Var%
Net Sales
162.21
119.70
35.51%
152.67
132.73
15.02%
144.79
119.94
20.72%
140.71
122.13
15.21%
Expenses
141.88
105.75
34.17%
133.98
116.68
14.83%
127.64
106.14
20.26%
124.27
108.29
14.76%
EBITDA
20.34
13.95
45.81%
18.69
16.05
16.45%
17.14
13.79
24.29%
16.44
13.84
18.79%
EBIDTM
12.54%
11.65%
12.24%
12.09%
11.84%
11.50%
11.68%
11.33%
Other Income
3.16
2.16
46.30%
3.24
2.61
24.14%
2.62
2.86
-8.39%
2.33
3.00
-22.33%
Interest
0.31
0.16
93.75%
0.29
0.12
141.67%
0.24
0.35
-31.43%
0.16
0.29
-44.83%
Depreciation
3.39
3.14
7.96%
3.33
2.91
14.43%
3.19
2.76
15.58%
3.57
2.90
23.10%
PBT
19.81
12.82
54.52%
18.31
15.63
17.15%
16.34
13.54
20.68%
15.04
13.66
10.10%
Tax
4.71
3.63
29.75%
4.28
3.44
24.42%
4.28
3.74
14.44%
3.60
-1.13
-
PAT
15.10
9.19
64.31%
14.03
12.19
15.09%
12.07
9.80
23.16%
11.44
14.79
-22.65%
PATM
9.31%
7.68%
9.19%
9.19%
8.33%
8.17%
8.13%
12.11%
EPS
7.26
4.29
69.23%
6.75
5.60
20.54%
5.80
4.50
28.89%
5.47
6.79
-19.44%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Net Sales
600.38
513.08
465.93
427.60
328.85
307.27
352.20
Net Sales Growth
21.41%
10.12%
8.96%
30.03%
7.02%
-12.76%
 
Cost Of Goods Sold
377.89
298.90
290.66
261.41
211.60
187.67
226.32
Gross Profit
222.49
214.18
175.27
166.20
117.26
119.59
125.88
GP Margin
37.06%
41.74%
37.62%
38.87%
35.66%
38.92%
35.74%
Total Expenditure
527.77
452.86
413.51
372.91
287.39
268.76
312.87
Power & Fuel Cost
-
12.90
11.01
11.53
8.04
7.28
7.29
% Of Sales
-
2.51%
2.36%
2.70%
2.44%
2.37%
2.07%
Employee Cost
-
70.32
63.41
58.32
43.57
42.96
44.54
% Of Sales
-
13.71%
13.61%
13.64%
13.25%
13.98%
12.65%
Manufacturing Exp.
-
41.26
24.77
22.49
7.20
12.19
18.16
% Of Sales
-
8.04%
5.32%
5.26%
2.19%
3.97%
5.16%
General & Admin Exp.
-
9.75
9.43
5.73
5.21
10.58
6.19
% Of Sales
-
1.90%
2.02%
1.34%
1.58%
3.44%
1.76%
Selling & Distn. Exp.
-
14.60
10.68
8.39
8.79
5.32
6.16
% Of Sales
-
2.85%
2.29%
1.96%
2.67%
1.73%
1.75%
Miscellaneous Exp.
-
5.12
3.54
5.04
2.98
2.76
4.20
% Of Sales
-
1.00%
0.76%
1.18%
0.91%
0.90%
1.19%
EBITDA
72.61
60.22
52.42
54.69
41.46
38.51
39.33
EBITDA Margin
12.09%
11.74%
11.25%
12.79%
12.61%
12.53%
11.17%
Other Income
11.35
9.96
6.71
3.09
2.49
4.26
4.21
Interest
1.00
0.79
1.42
1.29
2.53
4.84
6.47
Depreciation
13.48
12.36
12.15
12.96
9.29
10.59
17.35
PBT
69.50
57.04
45.56
43.53
32.13
27.34
19.73
Tax
16.87
14.41
7.48
6.17
8.46
12.29
8.65
Tax Rate
24.27%
25.26%
16.42%
28.16%
26.33%
15.98%
43.84%
PAT
52.64
42.63
38.09
16.00
23.68
64.59
11.07
PAT before Minority Interest
52.64
42.63
38.09
15.74
23.68
64.59
11.07
Minority Interest
0.00
0.00
0.00
0.26
0.00
0.00
0.00
PAT Margin
8.77%
8.31%
8.18%
3.74%
7.20%
21.02%
3.14%
PAT Growth
14.51%
11.92%
138.06%
-32.43%
-63.34%
483.47%
 
EPS
25.31
20.50
18.31
7.69
11.38
31.05
5.32

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Shareholder's Funds
402.27
394.78
199.12
209.66
193.59
125.04
Share Capital
10.46
10.90
6.41
6.41
6.41
8.53
Total Reserves
388.99
382.07
192.71
203.25
187.17
116.51
Non-Current Liabilities
3.44
0.21
3.59
2.88
7.87
21.02
Secured Loans
0.11
0.44
0.83
1.21
5.82
18.14
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Provisions
2.02
1.57
1.37
1.19
1.06
1.46
Current Liabilities
121.24
93.99
93.42
125.29
96.22
143.09
Trade Payables
87.74
63.23
39.93
83.14
57.93
84.62
Other Current Liabilities
32.46
25.11
23.80
20.80
16.95
29.31
Short Term Borrowings
0.00
5.31
29.41
20.95
17.08
23.91
Short Term Provisions
1.04
0.33
0.28
0.41
4.25
5.26
Total Liabilities
526.95
488.98
296.13
337.83
297.68
289.15
Net Block
109.41
91.18
95.94
70.26
64.26
86.49
Gross Block
194.30
163.87
184.26
79.35
84.85
103.81
Accumulated Depreciation
84.89
72.69
88.32
9.09
20.59
17.32
Non Current Assets
173.41
107.32
101.81
169.80
177.21
145.19
Capital Work in Progress
14.78
8.01
0.04
0.00
4.58
52.56
Non Current Investment
0.00
0.00
0.00
94.00
101.45
0.19
Long Term Loans & Adv.
43.31
5.39
5.84
5.40
6.74
2.50
Other Non Current Assets
5.92
2.73
0.00
0.13
0.18
3.46
Current Assets
353.54
381.65
194.31
168.03
120.46
143.95
Current Investments
106.51
64.82
23.14
22.28
20.90
22.38
Inventories
74.74
58.71
41.46
49.32
19.03
35.05
Sundry Debtors
116.86
110.77
79.41
63.94
61.73
66.59
Cash & Bank
25.45
113.82
31.11
18.38
13.20
7.66
Other Current Assets
29.97
3.17
2.51
0.46
5.61
12.26
Short Term Loans & Adv.
28.66
30.36
16.67
13.65
5.28
11.74
Net Current Assets
232.29
287.67
100.89
42.74
24.24
0.86
Total Assets
526.95
488.97
296.12
337.83
297.67
289.14

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 18
Cash From Operating Activity
60.97
9.13
11.46
25.01
34.88
PBT
57.04
45.56
21.91
32.12
19.73
Adjustment
7.32
10.01
36.11
9.84
24.98
Changes in Working Capital
6.32
-37.57
-40.04
-3.53
-4.77
Cash after chg. in Working capital
70.68
18.01
17.99
38.43
39.94
Interest Paid
0.00
0.00
0.00
0.00
0.00
Tax Paid
-9.72
-8.88
-6.53
-13.43
-5.06
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-14.11
-154.58
-20.20
-14.34
-10.99
Net Fixed Assets
-37.20
12.42
-104.95
45.22
Net Investments
-41.69
-41.68
103.80
-3.50
Others
64.78
-125.32
-19.05
-56.06
Cash from Financing Activity
-43.74
130.09
0.78
-5.44
-26.05
Net Cash Inflow / Outflow
3.12
-15.36
-7.97
5.22
-2.16
Opening Cash & Equivalents
0.57
15.93
18.08
12.86
9.36
Closing Cash & Equivalent
3.69
0.57
15.93
18.08
7.20

Financial Ratios

Standalone /

Consolidated
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Book Value (Rs.)
190.89
180.31
109.36
327.03
301.96
218.50
ROA
8.39%
9.70%
4.97%
7.45%
22.01%
3.83%
ROE
10.76%
12.87%
7.70%
11.74%
40.92%
9.07%
ROCE
14.39%
14.88%
9.93%
15.05%
40.49%
14.54%
Fixed Asset Turnover
2.87
2.68
3.24
4.01
3.26
3.39
Receivable days
80.97
74.49
61.18
69.74
76.22
68.98
Inventory Days
47.47
39.24
38.74
37.93
32.12
36.31
Payable days
92.18
64.78
85.92
86.12
98.41
95.45
Cash Conversion Cycle
36.25
48.95
14.00
21.55
9.93
9.84
Total Debt/Equity
0.00
0.02
0.16
0.13
0.15
0.44
Interest Cover
73.38
33.16
17.99
13.72
16.89
4.05

Annual Reports:

FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014

News Update:


  • Windlas Biotech commissions injectable facility to manufacture small volume parenteral products
    2nd Apr 2024, 17:38 PM

    The facility has initiated manufacturing of commercial batches

    Read More
  • Windlas Biotech - Quarterly Results
    8th Feb 2024, 14:30 PM

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.